Kisspeptin-10 3mg

What Is Kisspeptin-10?

Kisspeptins are peptide fragments produced from the KISS1 precursor protein. Kisspeptin-10, also called KP-10, contains the shortest ten-amino-acid sequence that retains full intrinsic activity at the kisspeptin receptor.

Its sequence is Tyr–Asn–Trp–Asn–Ser–Phe–Gly–Leu–Arg–Phe-NH2. By activating KISS1R, formerly called GPR54, Kisspeptin-10 stimulates hypothalamic gonadotropin-releasing hormone, or GnRH. GnRH then signals the pituitary to release luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH.

This upstream position makes Kisspeptin-10 3 mg a valuable research tool for studying puberty, reproductive feedback, gonadotropin pulses, ovarian and testicular signalling, and disorders involving the hypothalamic–pituitary–gonadal axis.

Why Kisspeptin-10 Attracts Research Interest

How the Reproductive-Axis Signal Works

LH and FSH act on the gonads and participate in ovulation, follicle development, sperm production and sex-steroid synthesis. Because the reproductive axis operates through pulses and feedback loops, the timing and duration of KISS1R activation can substantially change the experimental result.

Research Findings at a Glance

Promising Areas of Research Interest

The positive scientific interest surrounding Kisspeptin-10 3 mg spans several important reproductive pathways:

• GnRH pulse generation: examining how upstream hypothalamic signals control pituitary gonadotropin release.
• Puberty biology: studying the KISS1/KISS1R system as a gatekeeper of reproductive-axis activation.
• Male reproductive signalling: measuring LH pulse frequency, FSH and downstream testosterone responses.
• Female cycle physiology: investigating why responsiveness changes across follicular, preovulatory and luteal phases.
• Hypothalamic amenorrhea: evaluating whether kisspeptin signalling can reveal or restore dormant reproductive-axis activity.
• Fertility science: examining oocyte maturation and safer reproductive-hormone triggering strategies.
• Sexual-brain processing: exploring reproductive neurobiology, attraction and desire in early proof-of-concept studies.

These findings make Kisspeptin-10 a compelling HPG-axis research compound. They do not establish treatment benefits for infertility, PCOS, amenorrhea, low testosterone, low sexual desire or menstrual irregularity.

Kisspeptin-10 Compared with Kisspeptin-54

Understanding the PCOS Research

PCOS is associated with complex changes in GnRH pulse frequency, LH secretion, ovarian androgen production and metabolic signalling. Because kisspeptin neurons help organize GnRH pulses, the KISS1/KISS1R system is an appealing target for understanding this altered feedback network.

Studies have reported differences in circulating kisspeptin levels and KNDy-neuron signalling among women with PCOS. However, results are not fully consistent, and higher kisspeptin activity may be part of the dysregulation rather than a deficiency that simply needs replacement.

Therefore, the PCOS literature provides a strong rationale for mechanistic research but does not show that Kisspeptin-10 restores normal cycles, improves fertility or corrects the LH:FSH ratio.

Experimental Route and Dose Evidence

Published kisspeptin research spans KP-10, KP-54 and longer-acting receptor agonists. Studies have used different routes, quantities, infusion lengths, reproductive states and clinical settings. Acute and repeated exposure can also produce very different hormonal responses.

No standardized human dose, cycle length, injection schedule or product-specific administration protocol has been established for this product. The 3 mg designation describes the total laboratory quantity in the vial and should not be interpreted as a dose or administration instruction.

Safety and Evidence Context

Human kisspeptin studies have generally reported favourable short-term tolerability under controlled conditions. However, the long-term safety profile of Kisspeptin-10 remains incomplete, and reproductive-axis responses are highly dependent on biological context.

Repeated stimulation may produce tachyphylaxis, meaning a reduced hormone response over time. Excessive or poorly timed activation could also disrupt normal GnRH pulsatility, ovarian-cycle timing or gonadal feedback rather than improving it.

Overall, direct human endocrine findings strongly support continued research. More controlled studies are required before conclusions can be drawn about fertility, pregnancy-related use, PCOS, amenorrhea, testosterone support, sexual function or long-term hormonal effects.

Compare Related Research Options

These products investigate distinct neuroendocrine pathways and should not be treated as interchangeable. Combining research compounds does not guarantee additive or synergistic results.

Research References

1. Swolverine: Kisspeptin, the female hormone axis, fertility and PCOS — secondary educational source used as a topic guide.
2. Seminara et al. (2003) — KISS1R/GPR54 mutations and the regulation of human puberty.
3. George et al. (2011) — Kisspeptin-10, LH secretion and pulse frequency in men.
4. Jayasena et al. (2011) — sex- and cycle-dependent reproductive-hormone responses to Kisspeptin-10.
5. Jayasena et al. (2009) — acute gonadotropin stimulation and tachyphylaxis with kisspeptin-54 in hypothalamic amenorrhea.
6. Jayasena et al. (2014) — kisspeptin-54 and oocyte maturation during IVF.
7. Abbara et al. (2015) — oocyte maturation in women at high risk of ovarian hyperstimulation syndrome.
8. Abbara et al. (2017) — second-dose kisspeptin-54 research and oocyte yield.
9. Thurston et al. (2022) — kisspeptin and sexual-brain processing in women with low sexual desire.
10. Kokori et al. (2024) — review of kisspeptin as a potential PCOS biomarker.
11. PubChem: Kisspeptin-10 compound record.

Research-use notice: Kisspeptin-10 3 mg is presented for laboratory research and analytical discussion only. It is not intended to diagnose, treat, cure or prevent disease, or for human or animal use. This information is not medical advice or an administration guide.